Tongji Hospital, Tongji Medical college
Welcome,         Profile    Billing    Logout  
 31 Trials 
19 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Li, Ting
BEconneCTD-ILD, NCT06572384: A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease

Recruiting
3
440
Europe, Japan, US, RoW
Belimumab, BENLYSTA, GSK1550188, Placebo
GlaxoSmithKline
Lung Diseases, Interstitial
10/28
12/28
NCT06716606: A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

Recruiting
3
225
RoW
Belimumab
GlaxoSmithKline, ICON plc
Bronchial Diseases
08/28
01/30
ALKIVIA, NCT05523167 / 2021-001277-23: A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants with Active Idiopathic Inflammatory Myopathy.

Recruiting
2/3
240
Europe, Canada, Japan, US, RoW
EFG PH20 SC, PBO
argenx, argenx BV
Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
12/26
02/27
BLISSc-ILD, NCT05878717: A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

Hourglass Jan 2021 - Jun 2021 : Submission in combination with rituximab for SLE
Recruiting
2/3
300
Europe, Japan, US, RoW
Belimumab, BENLYSTA™, GSK1550188, LymphoStat-B™, BENLYSTATM, GSK1550188, LymphoStat-B™, Placebo
GlaxoSmithKline
Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
07/27
07/27
NCT06711991: A Clinical Trial of TQC3927 Powder for Inhalation in Chronic Obstructive Pulmonary Disease

Not yet recruiting
1
48
RoW
TQC3927 powder for inhalation, TQC3927 powder for inhalation placebo
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chronic Obstructive Pulmonary Disease
12/25
01/26
Yuan, Xianglin
NCT03236649: The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects

Terminated
3
89
RoW
Icaritin, Sorafenib Tosylate Tablets
Beijing Shenogen Biomedical Co., Ltd, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Eastern Theater General Hospital,QinHuai District Medical Area, Peking University Cancer Hospital & Institute, Chinese PLA General Hospital, Beijing Hospital, General Hospital of Chinese Armed Police Forces, Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Jinan Central Hospital, Linyi Cancer Hospital, The First Affiliated Hospital of Anhui Medical University, Anhui Provincial Hospital, The First Affiliated Hospital with Nanjing Medical University, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China, Nanfang Hospital of Southern Medical University, First People's Hospital of Foshan, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Tianjin Medical University Cancer Institute and Hospital, The Fourth Hospital of Hebei Medical University, Hunan Cancer Hospital, The First Hospital of Jilin University, 307 Hospital of PLA, Fudan University, Henan Cancer Hospital, Jilin Provincial Tumor Hospital, First Affiliated Hospital of Harbin Medical University, First Affiliated Hospital Bengbu Medical College, The First Affiliated Hospital of Soochow University, Tongji Hospital, Beijing YouAn Hospital
Hepatocellular Carcinoma (HCC)
02/22
02/22
NCT04714190: A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression

Recruiting
3
351
RoW
RC48-ADC, Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection, Paclitaxel injection, Taxol, Irinotecan Hydrochloride Injection, CAMPTO, Apatinib Mesylate Tablets, Aitan
RemeGen Co., Ltd.
Gastric Cancer, HER2 Overexpressing Gastric Carcinoma
12/24
06/25
GAPSO, NCT03801668: Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma

Recruiting
3
294
RoW
Albumin-bound Paclitaxel plus S-1, Oxaliplatin plus S-1
Huazhong University of Science and Technology, CSPC Ouyi Pharmaceutical Co., Ltd.
Gastric Cancer
12/22
03/23
NCT04385550: A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma

Not yet recruiting
3
528
RoW
Anlotinib hydrochloride capsule, AK105 injection, Paclitaxel injection, Docetaxel injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma
10/23
12/23
NAUTICALCRC, NCT05004350: A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.

Active, not recruiting
2
103
RoW
Encorafenib, Braftovi®, PF-07263896, W0090, LGX818, ONO-7702, Cetuximab, Erbitux®, C225, FOLFIRI, Folinic acid + Fluorouracil + Irinotecan
Pierre Fabre Medicament, Merck KGaA, Darmstadt, Germany
BRAF V600E, Metastatic Colorectal Cancer
12/23
01/25
NCT03941574: A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard Therapy

Recruiting
2
108
RoW
HLX10
Shanghai Henlius Biotech
MSI-H Solid Malignant Tumor
05/24
06/26
NCT06632262: A Phase 2 Clinical Study of ABSK061 and ABSK043

Not yet recruiting
2
202
RoW
ABSK061 + ABSK043, ABSK061+ABSK043 in combination with CAPOX
Abbisko Therapeutics Co, Ltd
HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors
11/29
06/30
NCT05934331: A LM-302 Combined With Toripalimab Phase II Study

Recruiting
2
276
RoW
LM302+Toripalimab, LM302+JS001
LaNova Medicines Zhejiang Co., Ltd.
Gastric Cancer, Pancreatic Cancer
07/25
01/26
CT041-ST-01, NCT04581473: Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection

Recruiting
1/2
192
RoW
CT041 autologous CAR T-cell injection, CAR T-cell injection, Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody）, Best support care(BSC)
CARsgen Therapeutics Co., Ltd., Peking University Cancer Hospital & Institute, Fudan University
Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma
06/24
06/38
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies

Recruiting
1/2
1300
Canada, US, RoW
SKB264
Klus Pharma Inc.
Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer
08/25
07/26
KYM901, NCT04805307: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901

Recruiting
1
162
RoW
CMG901
Keymed Biosciences Co.Ltd
Advanced Solid Tumor, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Pancreatic Cancer
05/24
10/24
CIBI343A101, NCT05458219: A First-in-human Study of IBI343 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors

Recruiting
1
470
US, RoW
IBI343
Innovent Biologics (Suzhou) Co. Ltd., Innovent Biologics, Inc., TigerMed
Locally Advanced Unresectable or Metastatic Solid Tumors
12/25
12/25
Widener, Nancy
ASTER, NCT05171049 / 2021-003076-14: A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE

Recruiting
3
1655
Europe, Canada, Japan, US, RoW
Abelacimab, MAA868, Apixaban, Eliquis
Anthos Therapeutics, Inc., Itreas
Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
12/26
02/27
MAGNOLIA, NCT05171075 / 2021-003085-12: A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE

Recruiting
3
1020
Europe, Canada, US, RoW
Abelacimab, MAA868, Dalteparin, Fragmin
Anthos Therapeutics, Inc., Itreas
Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
12/26
02/27

Download Options